Role of osteocytes in multiple myeloma bone disease

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 4, 2014, Pages 407-413

  Delgado Calle, Jesus ^a,b   Bellido, Teresita ^a,b,d   Roodman, G David ^c,d  

^a Department of Anatomy and Cell Biology ^*  (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Osteoclasts; Osteocytes; Receptor activator of nuclear factor kappa b ligand; Sclerostin

Indexed keywords

CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

BIOSYNTHESIS; BONE; BONE DISEASE; HUMAN; METABOLISM; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

BONE AND BONES; BONE DISEASES; CYTOKINES; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOCYTES; RANK LIGAND; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84924259117     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000090     Document Type: Review

References (65)

1. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009; 23:435-441.
2. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32:290-292.
3. Greenberg AJ, Rajkumar SV, Therneau TM, et al. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28:398-403.
4. Allen MR, Burr DB. Bone modeling and remodeling. In: Burr D, Allen M, editors. Basic and Applied Bone Biology, 1st edn San Diego, United States: Elsevier; 2014. pp. 75-90.
5. Hauge EM, Qvesel D, Eriksen EF, et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001; 16:1575-1582.
6. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 2007; 22:1-6.
7. Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009; 174:239-247.
8. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2013; 94:25- 34.
9. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26:229- 238.
10. Poole KE, Van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19:1842-1844.
11. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17:1231- 1234.
12. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17:1235-1241.
13. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. CellMetab 2007; 5:464- 475.
14. Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Min Res 2006; 21:605-615.
15. Bellido T. Osteocyte apoptosis induces bone resorption and impairs the skeletal response to weightlessness. BoneKEy-Osteovision 2007; 4:252- 256.
16. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28:244-250.
17. Andersen TL, Soe K, Sondergaard TE, et al. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 2010; 148:551-561.
18. Taube T, Beneton MNC, McCloskey EV, et al. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49:192-198.
19. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995; 90:721-724.
20. Silvestris F, Cafforio P, Tucci M, et al. Upregulation of osteoblast apoptosis by malignant plasma cells: A role in myeloma bone disease. Br J Haematol 2003; 122:39-52.
21. Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24:986-991.
22. Choi SJ, Oba T, Callander NS, et al. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 2003; 101:3778-3783.
23. Silbermann R, Bolzoni M, Storti P, et al. Bone marrow monocyte/macrophage derived activin a mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia 2014; 28:951-954.
24. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005; 208:252-266.
25. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106:2472-2483.
26. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand [RANKL]. Exp Hematol 2004; 32:685-691.
27. Plotkin LI. Apoptotic osteocytes and the control of targeted bone resorption. Curr Osteoporos Rep 2014; 12:121-126.
28. Cardoso L, Herman BC, Verborgt O, et al. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009; 24:597-605.
29. Noble B. Microdamage and apoptosis. Eur J Morphol 2005; 42:91-98.
30. O'Brien FJ, Brennan O, Kennedy OD, et al. Microcracks in cortical bone: How do they affect bone biology? Curr Osteoporos Rep 2005; 3:39-45.
31. Kennedy OD, Herman BC, Laudier DM, et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone 2012; 50:1115-1122.
32. Brennan O, Kennedy OD, Lee TC, et al. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res 2011; 29:419- 424.
33. Giuliani N, Ferretti M, Bolzoni M, et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 2012; 26:1391-1401.
34. Al-Dujaili SA, Lau E, Al-Dujaili H, et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem 2011; 112:2412-2423.
35. Bivi N, Condon KW, Allen MR, et al. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Min Res 2012; 27:374-389.
36. Eisenberger S, Ackermann K, Voggenreiter G, et al. Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo. J Pathol 2008; 214:617-626.
37. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011; 49:50-55.
38. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-323.
39. Yoshida H, Hayashi S-I, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442-444.
40. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone 2013; 54:258-263.
41. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581-11586.
42. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527-3533.
43. Schmiedel BJ, Scheible CA, Nuebling T, et al. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res 2013; 73:683-694.
44. Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma 2009; 9:430-435.
45. Sordillo EM, Pearse RN. RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 2003; 97 (Suppl 3):802-812.
46. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 2009; 84:650-656.
47. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factorkappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003; 63:5438-5445.
48. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromalcells andmyelomacells viaVCAM-1andalpha[4]beta[1]-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96:1953-1960.
49. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa Bligand [RANKL] in T lymphocytes: A potential role in multiple myeloma bone disease. Blood 2002; 100:4615-4621.
50. Delgado-Calle J, Bellido T, Roodman GD. Direct cell-to-cell interactions between osteocytes and multiple myeloma [MM] cells upregulate Sost and downregulate OPG expression in osteocytes: evidence for osteocytic contributions to MM-induced bone disease. Blood 2013; 122:3140.
51. Weivoda MM, Oursler MJ. Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. Curr Osteoporos Rep 2014; 12:107-114.
52. Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199:805-814.
53. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 2004; 35:828-835.
54. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280:19883-19887.
55. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003; 88:5778-5783.
56. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39:91-97.
57. Li X, Niu Q-T, Sun N, et al. Mice lacking sclerostin have increased bone formation and bone strength. Calcif Tissue Int 2007; 80:S24; Suppl 1.
58. Ke HZ, Richards WG, Li X, et al. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33:747-783.
59. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction postbortezomib monotherapy. Int J Cancer 2012; 131:1466-1471.
60. Brunetti G, Oranger A, Mori G, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci 2011; 1237:19-23.
61. Wang XT, He YC, Zhou SY, et al. Bone marrow plasma macrophage inflammatory protein protein-1 alpha [MIP-1 alpha] and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. Leuk Res 2014; 38:525-531.
62. Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 2011; 1:e27.
63. Habibi H, Abroun S, Hajifathali A, et al. Osteogenic inhibition in multiple myeloma. Cell J 2013; 15:266-271.
64. Mabilleau G, Mieczkowska A, Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 2010; 27:925-932.
65. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011; 6:e25900.